Medicare Freeze Slams Suppliers Nationwide

In a move that could block billions in suspicious Medicare payments, federal officials have quietly frozen new enrollments for certain medical supply companies while political fights rage elsewhere in Washington.

Story Snapshot

Centers for Medicare & Medicaid Services (CMS) has ordered a six-month nationwide freeze on new Medicare enrollments for seven types of durable medical equipment medical supply companies.
The moratorium aims to stop fraud, waste, and abuse in Medicare, especially around expensive equipment and transplant-related supplies, and can be extended in six-month chunks.
Existing suppliers can keep billing, but new businesses and ownership changes in the targeted categories are blocked, hitting mergers and small start-ups alike.
Vice President JD Vance and CMS Administrator Dr. Mehmet Oz are touting the move as a “detect and prevent” crackdown, while critics say it shows how blunt federal power can hurt honest providers too.

What CMS Just Did to Medical Supply Companies

On February 27, 2026, the Centers for Medicare & Medicaid Services (CMS) put in place a nationwide moratorium that stops new Medicare enrollments for seven kinds of durable medical equipment, prosthetics, orthotics, and supplies medical supply companies. These categories include basic medical supply companies and those with orthotics, prosthetics, pedorthic staff, registered pharmacists, or respiratory therapists on their teams. CMS says these companies have a high risk of fraud, waste, or abuse, making a freeze necessary to protect taxpayers.

The moratorium applies to initial enrollment applications, which means any new supplier in those seven categories is blocked from joining Medicare for now. It also applies to some changes in majority ownership that would normally trigger a new enrollment under Medicare rules, so company buyouts and mergers are affected as well. Current suppliers that are already enrolled can keep operating and billing Medicare as long as they do not need to submit a new initial application. CMS says the freeze will last six months but can be extended in six-month periods if needed.

Dr. Oz, Fraud Crackdowns, and the “Detect and Prevent” Push

Federal officials frame this moratorium as part of a larger move from a “pay and chase” system to a “detect and prevent” model, where suspicious claims and risky suppliers are stopped before money goes out the door. Vice President JD Vance and CMS Administrator Dr. Mehmet Oz have linked the action to alarming spikes in certain Medicare claims, including transplant and tissue-related billing, and say the new freeze will block millions in likely fraudulent payments. CMS also launched a “CRUSH” request for information to collect data and ideas on suspicious patterns in health care billing.

Supporters see this as a win for taxpayers who are tired of reading about billion-dollar fraud schemes while Washington argues over other topics. They point to past durable medical equipment crackdowns where enrollment moratoria helped cut off fly-by-night companies that billed Medicare for items patients never received or did not need. At the same time, critics note that Dr. Oz has drawn fire for comments about insurance usage and fraud that some experts say show a shaky grasp of how coverage is supposed to work, raising questions about how these crackdowns are explained to the public.

Who Gets Hurt: Legitimate New Suppliers and Patients

Because the moratorium blocks all new enrollments in the seven medical supply company types, it sweeps up honest businesses along with suspected bad actors. Legal and industry alerts warn that small practices hoping to open sleep centers with positive airway pressure devices, or new orthotic and prosthetic facilities that chose a “medical supply company” label on their forms, may now find their Medicare applications automatically denied. Trade groups have already asked CMS to clarify that individual orthotic and prosthetic suppliers without medical supplies are not covered by the freeze, and CMS has given some narrow confirmations.

For patients, the impact may be uneven. Existing suppliers can keep serving people and billing Medicare, so the agency expects no major short-term access crisis. But in communities where only one or two honest providers were planning to enter the market, especially rural areas, the moratorium could delay new options for seniors who need equipment like wheelchairs, braces, or breathing devices. This is exactly the kind of “one-size-fits-all” federal action that many Americans on both the right and the left criticize: it goes after fraud but can lock out honest players at the same time.

Deep State Fears, Media Spin, and What Comes Next

One source of confusion is who gets credit or blame for this move. Official documents from CMS and the Federal Register describe the moratorium as an agency action, not a personal decree from Dr. Oz, yet some partisan outlets frame it as “Dr. Oz’s crackdown.” That split fuels worries among both conservatives and liberals who feel that unelected bureaucrats and political appointees make big decisions out of the spotlight, while the headlines turn complex regulatory steps into simple talking points. Legal advisories instead focus on how providers must respond, treating the moratorium as another example of sudden top-down rule changes that businesses have to absorb.

The U.S. Centers for Medicare and Medicaid Services, led by Mehmet Oz, has regulatory power over California’s plan for the managed care tax.- https://t.co/AX4uUVJhi0

— CPA Practice Advisor (@cpapracadvisor) July 9, 2026

CMS has the power to extend the moratorium in six-month blocks, and will review data before deciding whether to lift or renew it. Advocates for more transparency say the agency should release detailed audit reports showing how much fraud was tied to these seven medical supply company types, and how much money is truly being saved. Without that hard information, many Americans who already doubt Washington’s honesty see this as one more case where the government uses a broad tool to fix a problem it has not fully explained, leaving taxpayers to wonder whether the cure will hurt as much as the disease.